Drug name - Rydapt

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222244 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2022

(a month ago)

US7973031 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2028

(5 years from now)

US8575146 NOVARTIS Pharmaceutical uses of staurosporine derivatives
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
Orphan Drug Exclusivity (ODE) Apr 28, 2024

Drugs and Companies using MIDOSTAURIN ingredient

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy; Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in